Clemson Rural Health, Guardian Research Network Partner to Improve Outcomes
Companies to collaborate on facilitating clinical trials in historically underserved regions.
Guardian Research Network (GRN) announced in a company press release that it has been joined by Clemson Rural Health to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN’s healthcare database is expected to help Clemson Rural Health bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.
"Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman, CEO, GRN. "Bringing this innovative team into our consortium demonstrates our unwavering commitment to improving access to cutting-edge studies in underserved communities. I look forward to the work we will accomplish together in our shared mission of driving community health advancements."
Reference: Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health. PR Newswire. October 3, 2023. Accessed October 10, 2023. https://www.prnewswire.com/news-releases/clemson-rural-health-joins-forces-with-guardian-research-network-to-improve-community-health-301945161.html
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
